FindTrial
Sign In

Comparison of three drugs used in patient of Acute uncomplicated bacterial tonsillitis

Comparative efficacy and safety of Co-Amoxyclav, Cefpodoxime proxetil, and Levofloxacin in Patient with Acute uncomplicated bacterial tonsillitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089170
Enrollment
107
Registered
2025-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J398- Other specified diseases of upperrespiratory tract

Interventions

Intervention1: Co-Amoxyclav: Oral Co-Amoxyclav 625mg Three times a day for 7 days Control Intervention1: Co-Amoxyclav: Co-Amoxyclav 625mg three times a day for 7 days Control Intervention2: Cefpodoxim

Sponsors

Dr Nadeem Ahmed
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A written consent for participation in the study. Patients suffering from acute uncomplicated bacterial tonsillitis.

Exclusion criteria

Exclusion criteria: Age below 18 years Viral Tonsillitis Tonsillitis with complications Tonsillitis with co existing lower respiratory tract infection Sinusitis Patients with renal and hepatic dysfunction

Design outcomes

Primary

MeasureTime frame
Comparative efficacy and safety of co-amoxyclav, cefpodoxime proxetil, and levofloxacin in patient with acute uncomplicated bacterial tonsillitisTimepoint: 3 days, 5 days, 7 days—

Secondary

MeasureTime frame
Comparative efficacy and safety of co-amoxyclav, cefpodoxime proxetil, and levofloxacin in patient with acute uncomplicated bacterial tonsillitisTimepoint: 3 days, 5 days, 7 days—

Countries

India

Contacts

Public ContactDr Nadeem Ahmed

Santosh Deemed to be University

drsajidrana@gmail.com9810849797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026